Expert opinion on biological therapyHumansUstekinumabDouble-Blind MethodBiosimilar PharmaceuticalsMale
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.
Jacek C Szepietowski, Adam Reich, Steven R Feldman, Grazyna Pulka, Lally Mekokishvili, Nino Tsiskarishvili, Inese Svarca, Airi Poder, Gursharan Singh, Sarika Deodhar, Kuldeep Kumar, Ashwani Marwah, Subramanian Loganathan, Elena Wolff-Holz, Sandeep N Athalye
Published: 202510.1080/14712598.2025.2576506
Abstract
BACKGROUND: The STELLAR-2 study compared the efficacy, safety, immunogenicity, and pharmacokinetics of Bmab 1200 with reference ustekinumab through Week 52 in patients with moderate-to-severe chronic plaque psoriasis. RESEARCH DESIGN AND METHODS: In…
Preview only. Read the full abstract at the source